Supporting this hypothesis, previous studies have demonstrated elevated rates of pathogenic mutations in genes other than BRCA1 and BRCA2 (6–7%) [3, 8] among women with ovarian cancer. The gene discussed is BRCA2; the disease is ovarian cancer.